Efficacy Analysis Of Hemoperfusion In 72 Children With Henoch-Schonlein Purpura

Objective: To explore the clinical curative effect of hemoperfusion with Henoch-Schonlein purpura in children and the indications of the blood perfusion technique treated Henoch-Schonlein purpura.Methods: Clinical data of total 72 patients with Henoch-Schonlein purpura treated by hemoperfusion (blood perfusion group) during January 2009 to October 2010 in our hospital were retrospectively analyzed, comparaed with 80 patients with Henoch-Schonlein purpura who were not treated by hemoperfusion (no blood perfusion group) during August 2010 to October 2010 in our hospital.Results:1) The treatment criteria of hemoperfusion in our hospital: rash symptoms heavy, repeatedly, the digestive tract symptoms, blood vessels neuropathic edema obvious and (or) use short-range vein corticosteroids for people with poor effect.2) Hemoperfusion has obvious effect on easing clinical symptoms caused by acute inflammation in Henoch-Schonlein purpura. Easing gastrointestinal symptoms must faster than blood vessels neuropathic edema (P = 0.002). There is no obvious difference between alleviating gastrointestinal symptom and joint symptom. Easing blood vessels neuropathic edema and joint swelling also has no obvious difference. The positive rate of urinary has no difference between before and after blood perfusion(P>0.05).3) 23 out of 49 cases follow-up have symptom relapse after discharge.22 cases rash relapse. Seven patients with obvious urinary protein have done renal biopsy. five cases, renal biopsy pathology reports are Henoch-Sch?nlein Purpura nephritisâ…¢level.4) Most patients, parents satisfied with curative effect of hemoperfusion.5) The proportion of boys with Henoch-Schonlein purpura is higher than girls in blood perfusion group compared with the no blood perfusion group (P = 0.011). The length of time in the hospital is longer in blood perfusion group compared with the no blood perfusion group (P < 0.01). Clinical classification, mixed model is more common in blood perfusion group (P =0.009), and simple model is more common in no blood perfusion group (P = 0.009). The proportion of kidney damage is higher in the blood perfusion group (P = 0.033).6) The proportion of using hormone to treat HSP in blood perfusion group is significantly higher than that in the no blood perfusion group in the outer court and our hospital (P < 0.01). Clinical treatment effect is much better in no blood perfusion group than that in the blood perfusion group (P < 0.01).Conclusion:1) Heperfusion is a safe and effective therapy to ease clinical symptoms caused by acute inflammation in Henoch-Schonlein purpura, but has no preventive function on rash recurrence and kidney damage.2) Heperfusion is a good choice to those patients who have heavy acute inflammation and(or) use short-range vein corticosteroids with poor effect.